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Introduction {#sec005}
============

Small cell lung cancer (SCLC) accounts for 15% of all lung cancers. The two-drug combination of etoposide and cisplatin remains the standard of care for SCLC \[[@pone.0156494.ref001]\]. Limited-stage small cell lung cancer (LS-SCLC), which is defined as disease that can be encompassed within reasonable radiotherapy fields, accounts for one-third of all cases of SCLC at diagnosis \[[@pone.0156494.ref002]\]. Concurrent chemo-radiotherapy (CRT) is the standard treatment for LS-SCLC and is widely used in clinical practice \[[@pone.0156494.ref003],[@pone.0156494.ref004]\]. CRT, along with prophylactic cranial irradiation (PCI), has yielded a wide-ranging median overall survival (OS) of 15.5 to 28.5 months \[[@pone.0156494.ref005],[@pone.0156494.ref006]\].

Thoracic radiotherapy (TRT) is a critical component of the treatment of LS-SCLC. The efficacy of TRT is closely related to the radiation dose, but this treatment strategy is more complicated in clinical practice. Currently, total doses that range from 45--50 Gy have been used in order to limit toxicity but maintain the efficacy \[[@pone.0156494.ref007]\]. Previous data have indicated that doses of 45--50 Gy are associated with a high rate of locoregional failure, and a dose-response is still seen at doses ≥50 Gy, which suggests the feasibility of high-dose radiation \[[@pone.0156494.ref008],[@pone.0156494.ref009]\]. Attempts have been made to administer high-dose radiation, but unfortunately, CALGB 39808, 30002 and 30202 failed to demonstrate the superiority of high-dose (70 Gy) radiation \[[@pone.0156494.ref010]\]. Some experts ascribed this to the prolonged overall radiation time (ORT) of the 70 Gy dose. In fact, several factors including single dose, fraction scheme, as well as the ORT may have an impact on the outcome.

The biological effective dose (BED) is based on tissue/tumor radiosensitivity, dose per fraction, total number of doses and the ORT \[[@pone.0156494.ref011]--[@pone.0156494.ref013]\]. Because it is a combination of both physical and radiobiologic factors, the BED could reflect the amount of lethal damage to a given tissue at an established dose over time and its biological response \[[@pone.0156494.ref014]\]. Because the transformation to the BED allows for the comparison of different radiation schedules, the BED is now widely used in the assessment of radiotherapy \[[@pone.0156494.ref015]\]. TRT plays an important role in the treatment of LS-SCLC, but the optimal radiation dose/fraction remains elusive. This study reviewed current evidence and explored the dose-response relationship within the perspective of BED.

Materials and Methods {#sec006}
=====================

Publication Search {#sec007}
------------------

We searched PubMed, Web of Science, and the Cochrane Library for trials that were published from 1966 to Aug 25, 2015. The search strategy used both MeSH terms and free-text words to increase sensitivity. The following search terms were used: "limited stage/limited disease", "small cell lung cancer/carcinoma", "LS-SCLC/LD-SCLC", and "radiotherapy/radiation". This study was approved by the Ethics Committee of Hangzhou First People's Hospital.

Inclusion and Exclusion criteria {#sec008}
--------------------------------

The inclusion criteria were as follows: (1) Prospective studies ≥1 group containing TRT for LS-SCLC; (2) To minimize heterogeneity, we only included studies in which the chemotherapy regimen comprised etoposide and cisplatin (EP) or etoposide and carboplatin (EC); (3) Studies that reported the local relapse (LR), overall survival (OS), and progression-free survival (PFS). The exclusion criteria were as follows: (1) Patients who responded only to chemotherapy but who also received TRT; (3) Letters, editorials, expert opinions, case reports and reviews; (4) Studies without usable data; (5) Duplicate publications.

Data extraction {#sec009}
---------------

Two investigators independently extracted the data from the eligible studies, and disagreements were resolved by discussion with a third investigator. For each study, the following information was recorded: the first author, year of publication, number of patients, dose per fraction, total dose, ORT, LR, PFS, and OS.

Statistical analysis {#sec010}
--------------------

To examine the dose-response relationship between the BED and LR, OS, as well as PFS, linear regression analyses weighted by sample size were used. For the 1- to 5-year OS rate, the following methods were used to extract the data: (1) obtained directly from the publication; (2) calculated and retrieved from Kaplan-Meier Curves. For the median OS and median PFS (mOS and mPFS), the above-mentioned methods were also used. Statistical analysis was performed with the IBM SPSS version 22.0 software. *P* values less than 0.05 were considered statistically significant. For the calculation of the BED, the following formulas were used \[[@pone.0156494.ref016]\]: $$BED\mspace{2mu} = \mspace{2mu} nd\,*\,(1 + \frac{d}{\alpha/\beta}) - 0.693\,*\frac{t}{\alpha T_{pot}}$$

Where ***α/β*** = 10, ***α*** = 0.3, ***T***~***pot***~ = potential doubling time (5.6 days), ***n*** represents the total number of fractions, ***d*** represents the dose per fraction, ***t*** represents the total radiation time (days).

Results {#sec011}
=======

Characteristics of included studies {#sec012}
-----------------------------------

As shown in [Fig 1](#pone.0156494.g001){ref-type="fig"}, the electronic search yielded 508 records. After the titles and abstracts were screened, 33 full-text articles were assessed for eligibility. Finally, 19 articles \[[@pone.0156494.ref005],[@pone.0156494.ref006],[@pone.0156494.ref017]--[@pone.0156494.ref033]\] were included in this systematic review. Among these 19 trials, seven were conducted in Europe, eight were conducted in Asia and four were conducted in the United States. These 19 trials consisted of 29 arms with 24 concurrent and 5 sequential radiochemotherapy arms. In regards to chemotherapy, 4 studies had 7 EC-based arms and 15 studies had 22 EP-based arms. These studies are summarized in detail in [Table 1](#pone.0156494.t001){ref-type="table"}.

![Flowchart of this systematic review.](pone.0156494.g001){#pone.0156494.g001}
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###### Characteristics of 19 included studies.

![](pone.0156494.t001){#pone.0156494.t001g}

  Study                                    Year   Country       Phase   N     TRT              Manner       BED    Cycle Start RT   Chemotherapy                                                                                       mOS (months)   mPFS (months)   LR (%)
  ---------------------------------------- ------ ------------- ------- ----- ---------------- ------------ ------ ---------------- -------------------------------------------------------------------------------------------------- -------------- --------------- --------
  Gronberg\[[@pone.0156494.ref017]\]       2015   Norway        II      84    42Gy/15F/15d     Concurrent   45.9   2                cisplatin 75 mg/m2 day1, etoposide 100 mg/m2 days1-3; 21-day cycle                                 18.8           10.2            34
                                                                        73    45Gy/30F/15d     Concurrent   43.9   2                cisplatin 75 mg/m2 day1, etoposide 100 mg/m2 days1-3; 21-day cycle                                 25.1           11.4            50
  Xia\[[@pone.0156494.ref005]\]            2015   China         II      59    55Gy/22F/22d     Concurrent   56.4   2/3              cisplatin 25 mg/m2 days1-3, etoposide 70 mg/m2 days1-4; 21-day cycle                               28.5           19              15
  Sun\[[@pone.0156494.ref018]\]            2013   Korea         III     113   52.5Gy/25F/25d   Concurrent   49.9   1                cisplatin 70 mg/m2 day1, etoposide 100 mg/m2 days1-3; 21-day cycle                                 24.1           12.4            36.9
                                                                        109   52.5Gy/25F/25d   Concurrent   49.9   3                cisplatin 70 mg/m2 day1, etoposide 100 mg/m2 days1-3; 21-day cycle                                 26.8           11.2            48.1
  Hu\[[@pone.0156494.ref019]\]             2012   China         II      43    45Gy/30F/15d     Concurrent   43.9   3                cisplatin 80 mg/m2 day1, etoposide 100 mg/m2 days1-3; 21-day cycle                                 25.4           19.4            28.6
  Colaco\[[@pone.0156494.ref020]\]         2012   England       II      26    66Gy/33F/33d     Concurrent   60.6   2                cisplatin 60 mg/m2 day1, etoposide 120 mg/m2 days1-3; 21-day cycle                                 \-             \-              15.3
                                                                        12    45Gy/30F/15d     Concurrent   43.9   2                cisplatin 60 mg/m2 day1, etoposide 120 mg/m2 days1-3; 21-day cycle                                 \-             \-              40
  Komaki\[[@pone.0156494.ref032]\]         2012   USA           II      71    61.2Gy/34F/34d   Concurrent   58.6   2                cisplatin 60 mg/m2 day1, etoposide 120 mg/m2 days1-3; 21-day cycle                                 19             9.9             27
  Sculier\[[@pone.0156494.ref006]\]        2008   France        III     104   40Gy/15F/15d     Concurrent   42.7   1                cisplatin 90 mg/m2 day1, etoposide 100 mg/m2 days1-3; 21-day cycle                                 15.5           10.3            16
                                                                        100   40Gy/15F/15d     Concurrent   42.7   1                cisplatin 6 mg/m2 days1-5, 8--12, 15--19, etoposide 100 mg/m2 days1-3; 21-day cycle                17             10.1            19
  De Ruysscher\[[@pone.0156494.ref021]\]   2006   Netherlands   II      27    45Gy/30F/15d     Concurrent   43.9   1                carboplatin AUC5 day1, etoposide 120 mg/m2 days1-3; 21-day cycle                                   21             16              26
  McClay\[[@pone.0156494.ref022]\]         2005   USA           III     154   50Gy/25F/25d     Concurrent   46.4   4                cisplatin 80 mg/m2 day1, etoposide 80 mg/m2 days1-3; 21-day cycle                                  20.6           12.3            \-
  Chen\[[@pone.0156494.ref023]\]           2005   China         II      57    56Gy/40F/20d     Sequential   53.1   2 to 4           cisplatin 25--30 mg/m2 days1-3, etoposide 50--70 mg/m2 days1-3; 21-day cycle                       24             \-              27
  Qiao\[[@pone.0156494.ref024]\]           2004   China         NR      45    60Gy/30F/30d     Concurrent   55.5   1                carboplatin 100 mg days1-5, etoposide 100 mg days1-5; 21-day cycle                                 26             \-              24.2
                                                                        45    60Gy/30F/30d     Sequential   55.5   5                carboplatin 100 mg days1-5, etoposide 100 mg days1-5; 21-day cycle                                 19             \-              39.5
  Schild\[[@pone.0156494.ref033]\]         2004   USA           III     131   50.4Gy/28F/28d   Concurrent   43.0   4                cisplatin 30 mg/m2 days1-3, etoposide 130 mg/m2 days1-3; 28-day cycle                              20.6           \-              34
  Takada\[[@pone.0156494.ref025]\]         2002   Japan         III     114   45Gy/30F/15d     Concurrent   43.9   1                cisplatin 80 mg/m2 day1, etoposide 100 mg/m2 days1-3; 28-day cycle                                 27.2           11.9            18
                                                                        114   45Gy/30F/15d     Sequential   43.9   4                cisplatin 80 mg/m2 day1, etoposide 100 mg/m2 days1-3; 28-day cycle                                 19.7           10.2            18
  Sundstrom\[[@pone.0156494.ref026]\]      2002   Norway        III     105   42Gy/15F/15d     Concurrent   45.9   4                cisplatin 75 mg/m2 day1, etoposide 100 mg/m2 day1,oral etoposide 200 mg/m2 days2-4; 21-day cycle   14.5           \-              \-
  Skarlos\[[@pone.0156494.ref027]\]        2001   Greece        II      42    45Gy/30F/15d     Concurrent   43.9   1                carboplatin AUC6 days1-3, etoposide 100 mg days1-3; 21-day cycle                                   17.5           9.5             \-
                                                                        39    45Gy/30F/15d     Concurrent   43.9   4                carboplatin AUC6 days1-3, etoposide 100 mg days1-3; 21-day cycle                                   17             10.5            \-
  Turrisi\[[@pone.0156494.ref028]\]        1999   England       III     206   45Gy/25F/25d     Concurrent   39.5   1                cisplatin 60 mg/m2 day1, etoposide 120 mg/m2 days1-3; 21-day cycle                                 19             \-              52
                                                                        211   45Gy/30F/15d     Concurrent   43.9   1                cisplatin 60 mg/m2 day1, etoposide 120 mg/m2 days1-3; 21-day cycle                                 23             \-              36
  Luo\[[@pone.0156494.ref029]\]            1999   China         NR      48    50Gy/25F/25d     Sequential   46.4   1                cisplatin 20 mg/m2 days1-5, etoposide 100 mg/m2 days1-3; 21/28-day cycle                           \-             \-              33.3
                                                                        46    50Gy/25F/25d     Sequential   46.4   6                cisplatin 20 mg/m2 days1-5, etoposide 100 mg/m2 days1-3; 21/28-day cycle                           \-             \-              43.5
  Jeremic\[[@pone.0156494.ref030]\]        1997   Japan         NR      52    54Gy/36F/18d     Concurrent   52.5   0                cisplatin 30 mg/m2 days1-3, etoposide 120 mg/m2 days1-3; 21-day cycle                              34             \-              6
                                                                        51    54Gy/36F/18d     Concurrent   52.5   3                cisplatin 30 mg/m2 days1-3, etoposide 120 mg/m2 days1-3; 21-day cycle                              26             \-              26
  Bunn\[[@pone.0156494.ref031]\]           1995   USA           III     108   45Gy/25F/25d     Concurrent   39.5   1                cisplatin 25 mg/m2 days1-3, etoposide 60 mg/m2 days1-3; 21-day cycle                               17             \-              \-

***BED*** biological effective dose, ***mOS*** median overall survival, ***mPFS*** median progression-free survival, ***LR*** local-relapse rate, ***F*** fraction, ***d*** day, ***AUC*** area under the curve, ***NR*** not reported

### Linear regression analysis of all included studies {#sec013}

In all, 2389 patients in 19 trials were included in this study. Twenty-five of 29 arms and 15 of 29 arms reported the mOS and mPFS, respectively. The mOS and mPFS ranged from 14.5 to 34 months and from 9.5 to 19.4 months, respectively. The results showed that a higher BED prolonged the mOS (R^2^ = 0.198, p\<0.001) and the mPFS (R^2^ = 0.045, p\<0.001) ([Fig 2A and 2B](#pone.0156494.g002){ref-type="fig"}). In order to explore the impact of the BED on long-term survival, we analyzed the correlation between the BED with the 1-, 3-, and 5-year OS. This analysis showed that an increased BED improved the 1-, 3-, and 5-year OS (R^2^ = 0.228, p\<0.001; R^2^ = 0.134, p\<0.001; R^2^ = 0.085, p\<0.001, respectively) ([Fig 2C--2E](#pone.0156494.g002){ref-type="fig"}). A 10-Gy increment added a 6.3%, a 5.1% and a 3.7% benefit with respect to the 1-, 3-, and 5-year OS, respectively. Previous data indicated that a total dose of 45--50 Gy was still associated with a high rate of locoregional failure, but whether an increased BED could decrease the LR rate was unknown. Therefore, we further analyzed the relationship between the BED and LR. The results showed that the BED was correlated with the incidence of LR (R^2^ = 0.09, p\<0.001)([Fig 2F](#pone.0156494.g002){ref-type="fig"}). A 10-Gy increment in the BED could decrease the LR rate by 7.1%. As significant heterogeneity was present across the included studies (small R^2^ value), we next performed subgroup analyses.

![**Association between BED and mOS (A), mPFS (B), 1-year OS (C), 3-year OS (D), 5-year OS (E), and LR (F) for all included studies.** Each point in the plot represents a value of one arm. The point size represents the sample size. All analyses were conducted by linear regression methods weighted by sample size. ***BED***, biological effective dose; ***mOS***, median overall survival; **1-, 3-, 5-year *OS***, 1-, 3, 5-year overall survival; ***LR***, local relapse](pone.0156494.g002){#pone.0156494.g002}

Analysis of concurrent chemo-radiotherapy {#sec014}
-----------------------------------------

Previous studies have indicated that concurrent chemo-radiotherapy is one of the optimal medical treatments for LS-SCLC. Therefore, we conducted this analysis to explore the dose-response relationship of the BED in the setting of concurrent chemo-radiotherapy. After the removal of 3 studies that reported only sequential chemo-radiotherapy \[[@pone.0156494.ref023],[@pone.0156494.ref024],[@pone.0156494.ref029]\], 2041 patients from 16 studies were finally included in subsequent subgroup analyses. The result revealed that a higher BED could prolong the mOS (R^2^ = 0.229, p\<0.001) and the mPFS (R^2^ = 0.034, p\<0.001) ([Fig 3A and 3B](#pone.0156494.g003){ref-type="fig"}). According to our calculated model, an increase in the BED from 45 Gy to 60 Gy added 6.5 months to the mOS. Moreover, our data showed that an increased BED improved the 1-, 3-, and 5-year OS ([Fig 3C and 3E](#pone.0156494.g003){ref-type="fig"}) and decreased the rate of LR (R^2^ = 0.147, p\<0.001)([Fig 3F](#pone.0156494.g003){ref-type="fig"}).

![**Association between BED and mOS (A), mPFS (B), 1-year OS (C), 3-year OS (D), 5-year OS (E), and LR (F) in the setting of concurrent chemo-radiotherapy.** Each point in the plot represents a value of one arm. The point size represents the sample size. All analyses were conducted by linear regression methods weighted by sample size. ***BED***, biological effective dose; ***mOS***, median overall survival; **1-, 3-, 5-year *OS***, 1-, 3, 5-year overall survival; ***LR***, local relapse](pone.0156494.g003){#pone.0156494.g003}

Discussion {#sec015}
==========

This study reviewed current evidence and explored the potential of high dose TRT for the treatment of LS-SCLC. Our results showed that an increased BED prolonged the OS and PFS. A 10-Gy increment also added a 6.3%, a 5.1% and a 3.7% benefit with respect to the 1-, 3-, and 5-year OS, respectively. A retrospective study enrolled 205 LS-SCLC patients and compared the outcomes of a high BED (\>57Gy) and a low BED (≤57Gy). That study demonstrated that the high BED (\>57 Gy) group had a significantly better OS and PFS.

Currently, the combination of platinum and etoposide is the standard chemotherapy for LS-SCLC. A meta-analysis of four eligible trials showed no differences in efficacy between cisplatin and carboplatin as a first-line treatment for SCLC \[[@pone.0156494.ref034]\]. In order to minimize chemotherapy-induced effects, we only included trials that adopted the cisplatin/carboplatin plus etoposide regimen. This study features seven EC-based arms and twenty-two EP-based arms.

In the late 1950s, the Veterans Administration Lung Study Group (VALSG) defined LS-SCLC as a disease that is confined to the ipsilateral hemithorax that could be treated in a single radiation field \[[@pone.0156494.ref035]\]. This definition indirectly illustrated the important role of RT in LS-SCLC. First-line chemotherapy alone could achieve a response rate of 60--70%, whereas the combination of chemotherapy and TRT further improved overall survival \[[@pone.0156494.ref003],[@pone.0156494.ref036],[@pone.0156494.ref037]\]. Efforts that explore the optimal TRT schedule are currently underway. In 2002, JCOG9104 evaluated the efficacy of concurrent and sequential TRT for LS-SCLC and demonstrated that concurrent TRT was more effective than sequential TRT \[[@pone.0156494.ref025]\]. In this study, 5 arms of 4 trials involved sequential TRT, while 24 arms of 17 trials involved concurrent TRT. We found that the BED was positively correlated with OS in the setting of concurrent TRT (p\<0.001). This suggested that a dose-response relationship still existed even in the case of a high BED (more than 45 Gy/30 F/15 d). A high BED strategy might be considered as an option in future trials.

Local treatment failure occurs in approximately 30% of LS-SCLC patients who are treated with the current standard therapy. LR is a major risk factor of survival. Our results showed that the BED was negatively correlated with LR (p\<0.001). A 10Gy increment in the BED could decrease the LR rate by 5.5%. This suggested that a decrease in local failure might eventually contribute to a benefit in OS in patients who are treated with a high BED. However, RTOG 0617 demonstrated patients with non-small cell lung cancer receiving a high dose of 74Gy had a worse survival than 60Gy in the era of PET-CT staging and modern radiotherapy \[[@pone.0156494.ref038]\]. Increased dose might offer better local control as well as potential survival benefit, while the corresponding toxicity could not be ingored. RTOG0617 focused on the prevention of radiation pneumonitis in the design, whereas it underestimated the importance of heart protection. Analysis showed elevated heart dose in high dose group might have increased mortality. QOL analysis of the trial indicated IMRT provided better normal tissue protection \[[@pone.0156494.ref039]\], suggesting increase dose to SCLC might employ advanced radiation technique and value the importance of normal tissue protection in the future trials.

SCLC is characterized by a high invasion rate and rapid proliferation. Total dose-based measurements underestimate the effect of accelerated proliferation during a course of radiation, especially 30--40 days after the initial dose is given. CALGB 39808, 30002 and 30202 compared the efficacy of 45 Gy and 70 Gy radiation in patients with LS-SCLC, but these trials failed to demonstrate the superiority of high-dose (70 Gy) radiation \[[@pone.0156494.ref010]\]. This failure might be ascribed to prolonged ORT in the setting of 70 Gy radiation. Previous studies reported the T~pot~ of SCLC ranged from 2.6 to 8.6 days \[[@pone.0156494.ref040]--[@pone.0156494.ref042]\]. The high proliferation rate makes repopulation extremely important during the late course of therapy. The ORT of the included trials ranged from 3 to 7 weeks. Therefore, it was necessary to take the ORT into account.

Many researchers proposed models to calculate the BED for SCLC. Among these models, we agreed with the model proposed by *Fowler JF*. \[[@pone.0156494.ref016]\] which took ORT and tumor doubling time into consideration simultaneously and was also used in the study of *schild* \[[@pone.0156494.ref043]\]. Our previous study also adopted this model to investigate the biological radiation dose-response for Chinese patients \[[@pone.0156494.ref044]\]. T~pot~ of SCLC ranged from 2.6 to 8.6 days reported by previous publication. In this study, T~pot~ was set to 5.6 days which was same with the study of *schild*. *Schild et al*. found the Pearson correlation coefficient of 0.81 between BED and 5-year survival indicating a strong positive correlation. Although it was well performed, the authors only incorporated 8 studies and newer studies were not included as limitation of publication time. In addition, the parameters of LR and PFS were not analyzed in that study. Thus, it is of importance to perform this study.

However, R^2^ values were small in both the mPFS and LR analyses. This may be explained by the following reasons: (1) to obtain survival data, researchers usually followed-up patients periodically, and therefore, it was relatively easy to record these data especially in prospective studies; (2) The evaluation of LR and mPFS depended on imaging examinations. Whereas different studies adopted different techniques including chest radiography, computed tomography or positron emission tomography, these techniques varied in their sensitivities. In addition, survival data could be obtained by telephone or other communication tools, whereas the evaluation of the PFS and LR was limited to the hospital. Patient compliance inevitably had an impact on the evaluation.

Nevertheless, our study has several limitations. The timing of radiotherapy (early vs. later), the dose schedule of chemotherapy, radiation schedule (once daily vs. twice daily), and the types of radiation (conventional, 3-dimensional, intensity-modulated radiation therapy) all yielded different outcomes. Compared to daily fractionation radiation, twice daily fractionation radiation showed better survival benefit \[[@pone.0156494.ref017],[@pone.0156494.ref020],[@pone.0156494.ref028]\]. Although twice daily fractionation radiation overcomes the problem of tumor repopulation and re-oxygenation, inconvenience of this schedule and compliance of patients limits its use. Most of the included articles were single-arm phase II studies with small sample sizes, and thus our results were prone to be influenced by chance errors even though we had performed these calculations after they were weighted by sample size. Patients from different regions who participated in studies that were conducted at different research centers increased the inherent heterogeneity and might have influenced the validity of the results. Furthermore, the time span of included publications was as long as 20 years. Advances in radiation techniques and radiographic diagnosis as well as new staging systems and supportive treatments have the potential to provide survival benefits. Nevertheless, this study still had certain implications that might contribute to the exploration of an optimal TRT scheme for LS-SCLC.

In **conclusion**, we thought it was necessary to conduct this systematic review. This study explored the correlation of BED with mOS, mPFS, 1-, 3-, and 5-year OS and LR. The results showed that an increased BED could prolong survival and decrease LR. Compared with the current accepted radiation scheme (45 Gy/30 F/15 d), a higher BED might be a feasible strategy.
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